SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing intense market attention as investors weigh its critical role in the AI infrastructure cycle against high expectations, leading to heavy options activity and polarized community debates over whether results are already priced in. Participants are closely monitoring the upcoming earnings for clarity on future demand, sector growth, and management guidance that could impact the broader market trajectory.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing significant volatility and downward pressure ahead of its upcoming earnings report, with community sentiment split between those viewing the price drop as a "bear trap" or value buying opportunity and others concerned about insider selling and tariff impacts. Investors remain deeply divided on the stock's future, as many weigh the potential for a growth rebound driven by successful brand acquisitions against the risks of sector rotation and institutional manipulation.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are seeing extreme volatility following earnings that topped analyst estimates but provided cautious forward guidance. The community remains sharply divided, with some investors accumulating shares on the dip as a long-term AI-driven growth play, while others fear the firm's business model faces existential disruption from emerging AI automation tools.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors react to bullish CEO commentary regarding positive GPS immunotherapy data, which is being framed as superior to current standards of care. The community is heavily focused on the potential for an imminent short squeeze and clinical milestones, creating a volatile environment as traders monitor institutional buying activity and the upcoming oncology conference presentation.

Micware Co. Ltd. engages in software development services and innovative IT solutions mainly focused on the automotive and mobility sectors. It operates through the following segments: Software Defined Vehicles (SDV), Location-Based Services (LBS), and Others. The SDV segment relates to the development and sale of software systems designed for SDV, including IVI system software and other mobility-enhancing software products, conducted by its Japanese subsidiaries. The LBS segment covers the development and licensing of in-vehicle navigation software systems, and other geographic data-based services for business-to-business customers, mainly serving end users. The Other segment comprises software development services conducted by overseas subsidiaries designed for SDV, and business-to-consumer mobile app services unrelated to in-vehicle navigation. The company was founded by Kenji Narishima in March 2003 and is headquartered in Kobe, Japan.

Micware Co. Ltd. - ADR

Micware is experiencing extreme volatility and heavy retail attention as traders speculate on its potential for a massive rally following a recent IPO. The community is actively debating whether the stock is a legitimate opportunity or a classic pump-and-dump scheme, with many watching for breakout levels while navigating multiple trading halts.

Applied Digital Corporation

Applied Digital is currently trending following a major lease announcement with a high-grade hyperscaler that pushed its contracted AI capacity past the gigawatt threshold, fueling significant community excitement about its long-term growth. Investors are actively discussing the stock's potential for further gains as it continues to expand its data center footprint, with many using the recent price volatility as an opportunity to add to their positions.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp

AEVEX Corp. is drawing significant community interest following its strong debut, fueled by its operational role in defense-tech and autonomous drone systems. Traders are actively debating the company's valuation and growth potential against established peers, with many focused on its substantial backlog and ability to secure key U.S. government contracts in an evolving defense environment.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending following news that the SEC has closed its three-year probe into the token, sparking a significant rally and community discussions regarding its potential to regain past highs. Traders are actively debating whether this movement represents a sustainable breakout or a temporary pump, while many enthusiasts highlight Zcash's privacy features and limited supply as catalysts for long-term growth.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending as investors debate the impact of advanced AI models like Anthropic's Mythos on cybersecurity software, with bullish sentiment focused on the stock's role in the new defensive infrastructure alongside Palo Alto Networks. While some community members worry about potential valuation compression and margin headwinds, others highlight the firm's critical platform expansion and persistent enterprise demand as institutional smart money continues to evaluate the sector's long-term resilience.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is trending as investors react to its position as a domestic supplier of high-precision optics for defense, space, and AI infrastructure, further bolstered by recent defense purchase orders. The community is actively debating the company's growth potential against its financial positioning, with discussions focused on its role in the U.S. defense supply chain and its ability to scale production for LEO satellite and AR military programs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher - Time to Buy?

Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 4.9% - Here's Why...

Polaryx Therapeutics (NASDAQ:PLYX) Stock Price Down 1.9%  - Time to Sell?

Polaryx Therapeutics (NASDAQ:PLYX) Trading Down 1.9% - Time to Sell...

<ul class="summary-bullets"><li>Polaryx Therapeutics went public via a direct listing on Feb. 2.</li><li>The biotech firm is developing treatments for lysosomal storage disorders (LSDs).</li><li>Stocktwits sentiment for PLYX shifted to ‘extremely bullish’ after the stock rally.</li></ul><p>Shares of Polaryx Therapeutics (PLYX), a newly listed clinical-stage biotech firm, surged 70% on Tuesday,&nbsp;its best session on record, spurring increased interest from retail traders on Stocktwits. The micro-cap stock surged 29% on Monday.</p><h2 class="st-heading-2"><strong>Biotech Stocks Drawing Interest</strong></h2><p>Polaryx is focused on rare neurodegenerative diseases and is currently testing its PLX-200 treatment aimed at treating lysosomal storage disorders (LSDs), genetic diseases where the body can’t break down certain molecules, causing harmful buildup inside cells.</p><p>Biotech names have been catching investors' eyes as they seek shelter from the market turbulence triggered by the US-Israel conflict with Iran. Drug stocks have emerged as a go-to safe haven amid all the geopolitical uncertainty this year: the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF</a> (XBI) has gained over 4% this year while the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust</a> (SPY) and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust Series 1</a> (QQQ) index funds (which track the benchmark U.S. indices) have shed about 1%.</p><p>Polaryx’s pipeline includes four drug candidates, namely, PLX-200, PLX-100, PLX-300, and PLX-400 for LSDs. The last three are still in the preclinical stage.</p><h2 class="st-heading-2"><strong>Recent Updates From PLYX</strong></h2><p>The recent uptrend in the stock was likely triggered as investors took note of the company’s research advances. The company&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nasdaq.com/articles/polaryx-initiate-soteria-phase-2-basket-trial-1h2026-stock?utm_source=chatgpt.com">announced</a> on Feb. 17 that it was moving forward with its phase-2 trial evaluating PLX-200 in four lysosomal storage disorders (LSDs) after receiving a “safe-to-proceed” letter from the Food and Drug Administration in October.</p><p>Last week, Maxim initiated coverage on the PLYX with a ‘Buy’ rating and $10 price target, which implies a 66% upside to the stock’s last close. The firm said it views PLX-200 as a differentiated offering, given its oral formulation and potential to address a broad spectrum of LSDs by targeting shared disease pathways.</p><h2 class="st-heading-2"><strong>Retail’s View On PLYX</strong></h2><p>On Stocktwits, retail sentiment for PLYX shifted to ‘extremely bullish’ as of early Wednesday, from ‘bullish’ the prior day, amid ‘extremely high’ message volume. The watcher count for&nbsp;<a href="https://stocktwits.com/symbol/PLYX">PLYX</a> on the platform increased nearly 50% over the past 24 hours.</p><p>Several users&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.stocktwits.com/NorthernMonkey1/message/647157001">said</a> they would be watching the stock in the coming days.</p><p>“$PLYX development stage biotech that traders tend to position in ahead of pipeline progress updates. These setups usually need sustained volume to get momentum going,” one trader&nbsp;<a href="https://stocktwits.com/topstockalerts/message/647155307">said</a>, explaining the prevailing view.</p><p>About 25 million PLYX shares exchanged hands on Tuesday, about nine times the stock’s average trading volume, according to Stocktwits data.</p><h2 class="st-heading-2"><strong>Stock Widely Down Since Listing</strong></h2><p>Polaryx’s recent gains come&nbsp;as a relief, as the stock slid sharply after its direct listing on the Nasdaq on Feb. 2. Shares currently trade at about one-tenth of their opening price of $45.00 that day.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-shuts-up-the-bears-as-ceo-touts-faster-cheaper-ai-wall-street-is-totally-buying-it/cZdANc5RIJT">Oracle Shuts Up The Bears As CEO Touts 'Faster, Cheaper' AI: Wall Street Is Totally Buying It</a></p>

Traders work on the floor of the New York Stock Exchange.

Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest?

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.

PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech

Equity

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.


Maxim Group Begins Coverage on Polaryx Therapeutics (NASDAQ:PLYX)

Maxim Group began coverage on Polaryx Therapeutics in a report on Friday. They set a "buy" rating and a $10.00 price objective on the stock...

Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 15.2% - Here's Why

Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 15.2% - Here's Why...

What's Going On With Polaryx Therapeutics Stock Wednesday?

Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement.read more...

Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans

Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders.read more...

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

PLYX
Polaryx Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest PLYX News

PLYXPolaryx Therapeutics Inc.